Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

- First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal...

Form 8-K - Current report

Form 8-K - Current report

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially...

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Form 305B2 - Filing [Trust Indenture Act]

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential...